▶ 0:03 · $PLTR · $AMD · the most asymmetric bet in history

episode briefing

the most asymmetric bet in history

2026-06-02 · 6 company · 2 thematic

sentiment

4 bull0 bear2 neu

speakers

Antonio Linares runs a concentrated six-stock portfolio plus micro investments, focusing on 'singularity scalers' — companies with proprietary data moats that compound value via AI scaling laws. He bought Palantir at ~$7, held through 2022-2024 drawdowns, and teaches a course on modern value creation processes. His framework emphasizes betting early on extraordinary companies, holding forever, and learning from concentrated mistakes.

quote

“As many of you know, I'm an early investor in AMD, $4.2 per share, that's when I got in. Same with Palantir, $7 per share. Roughly, these two investment ideas are different slightly different expressions of the same core investment thesis,…”

—antonio linares

now playing · $PLTR · $AMD

$PLTR···neutral· lowantonio linares

Early Palantir investment at $7 validated compute-to-intelligence thesis

Past investment at $7/share based on same compute-to-intelligence thesis; free cash flow per share now growing exponentially.

$AMD···neutral· lowantonio linares

Early AMD investment at $4.20 validated compute-to-intelligence thesis

Past investment at $4.20/share based on thesis that more compute translates to more intelligence; cited as proof of concept for current biology thesis.

$NAUT···bullish· mediumantonio linares

Nautilus proteomic platform reads biological code to target pathogens for engineered immune cells

Proteomic assay platform identifies specific pathogenic proteomic signatures, enabling precise engineering of T cells, NK cells, and iNKTs to target 'bad guys' — the essential 're…

$INKT···bullish· mediumantonio linares

MiNK's iNKT cell platform offers third immune reboot path via lipid recognition, lower toxicity

Invariant natural killer T cells target conserved lipid antigens rather than mutable peptides, enabling allogeneic use without CAR-T-like toxicity; lower toxicity allows higher do…

$IBRX···bullish· high· posantonio linares

Host discloses long position in ImmunityBio, adds shares on IL-15 immune reboot thesis

IL-15 superagonist durably reboots and weaponizes the immune system by binding macrophage receptors, triggering a cytotoxic flywheel; foundational horizontal platform with massive…

$HIMS···bullish· mediumantonio linares

Hims positioned as largest D2C healthcare platform, 'Costco for biomarkers' materializing

Hims is currently the biggest direct-to-consumer healthcare platform and could become the 'Costco for biomarkers' as biology scales, benefiting from the convergence of cheap seque…

←